MicroRNA-150 inhibits tumor invasion and metastasis by targeting the chemokine receptor CCR6, in advanced cutaneous T-cell lymphoma

Blood

Volumn 123, Issue 10, 2014, Pages 1499-1511

  Ito, Mitsugu ^a   Teshima, Kazuaki ^a   Ikeda, Sho ^a   Kitadate, Akihiro ^a   Watanabe, Atsushi ^a   Nara, Miho ^a   Yamashita, Junsuke ^b   Ohshima, Koichi ^c   Sawada, Kenichi ^a   Tagawa, Hiroyuki ^a  

^a AKITA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b AKITA UNIVERSITY   (Japan)

^c KURUME UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CD3 ANTIGEN; CD4 ANTIGEN; CD56 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR6; INTERLEUKIN 22; MACROPHAGE INFLAMMATORY PROTEIN 3ALPHA; MICRORNA; MICRORNA 150; MICRORNA 29A; MICRORNA 29B; MICRORNA 61; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; CHEMOTAXIS; CONTROLLED STUDY; CUTANEOUS T CELL LYMPHOMA; DOWN REGULATION; FEMALE; HUMAN; METASTASIS INHIBITION; MOUSE; NONHUMAN; PRIORITY JOURNAL; TUMOR INVASION; UPREGULATION;

ANIMALS; AUTOCRINE COMMUNICATION; CELL LINE, TUMOR; CHEMOKINE CCL20; CHEMOTAXIS; CLUSTER ANALYSIS; DISEASE MODELS, ANIMAL; GENE EXPRESSION; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; GENES, TUMOR SUPPRESSOR; HUMANS; INTERLEUKINS; LYMPHOMA, T-CELL, CUTANEOUS; MICE; MICRORNAS; NEOPLASM INVASIVENESS; NEOPLASM METASTASIS; NEOPLASM STAGING; RECEPTORS, CCR6; RNA INTERFERENCE; TRANSFECTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84897547431     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2013-09-527739     Document Type: Article

References (47)

1. Bartel DP. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell. 2004;116(2): 281-297.
2. Jaffe ES, Harris NL, Stein H, Campo E, Pileri SA, Swerdlow SH. Introduction and over review of the classification of the lymphoid neoplasms. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:158-178.
3. Esquela-Kerscher A, Slack FJ. Oncomirs - microRNAs with a role in cancer. Nat Rev Cancer. 2006;6(4):259-269.
4. Croce CM. Causes and consequences of microRNA dysregulation in cancer. Nat Rev Genet. 2009;10(10):704-714.
5. Iorio MV, Croce CM. MicroRNAs in cancer: small molecules with a huge impact. J Clin Oncol. 2009; 27(34):5848-5856.
6. Tagawa H, Ikeda S, Sawada K. Role of microRNA in the pathogenesis of malignant lymphoma. Cancer Sci. 2013;104(7):801-809.
7. Chang TC, Yu D, Lee YS, et al. Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet. 2008;40(1):43-50.
8. Jiang X, Huang H, Li Z, et al. Blockade of miR-150 maturation by MLL-fusion/MYC/LIN-28 is required for MLL-associated leukemia. Cancer Cell. 2012;22(4):524-535.
9. Watanabe A, Tagawa H, Yamashita J, et al. The role of microRNA-150 as a tumor suppressor in malignant lymphoma. Leukemia. 2011;25(8):1324-1334.
10. Ito M, Hiramatsu H, Kobayashi K, et al. NOD/ SCID/gamma(c)(null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002;100(9):3175-3182. (Pubitemid 35217065)
11. Ballabio E, Mitchell T, van Kester MS, et al. MicroRNA expression in Sezary syndrome: identification, function, and diagnostic potential. Blood. 2010;116(7):1105-1113.
12. Qin Y, Buermans HP, van Kester MS, et al. Deep-sequencing analysis reveals that the miR-199a2/ 214 cluster within DNM3os represents the vast majority of aberrantly expressed microRNAs in Sézary syndrome. J Invest Dermatol. 2012;132(5):1520-1522.
13. Ralfkiaer U, Hagedorn PH, Bangsgaard N, et al. Diagnostic microRNA profiling in cutaneous T-cell lymphoma (CTCL). Blood. 2011;118(22):5891-5900.
14. van Kester MS, Ballabio E, Benner MF, et al. miRNA expression profiling of mycosis fungoides. Mol Oncol. 2011;5(3):273-280.
15. Valleron W, Ysebaert L, Berquet L, et al. Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. Blood. 2012;120(19):3997-4005.
16. Desjobert C, Renalier MH, Bergalet J, et al. MiR- 29a down-regulation in ALK-positive anaplastic large cell lymphomas contributes to apoptosis blockade through MCL-1 overexpression. Blood. 2011;117(24):6627-6637.
17. Klein U, Lia M, Crespo M, et al. The DLEU2/ miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
18. Teshima K, Nara M, Watanabe A, et al. Dysregulation of BMI1 and microRNA-16 collaborate to enhance an anti-apoptotic potential in the side population of refractory mantle cell lymphoma [published online ahead of print May 20, 2013]. Oncogene.
19. Lim LP, Lau NC, Garrett-Engele P, et al. Microarray analysis shows that some microRNAs downregulate large numbers of target mRNAs. Nature. 2005;433(7027):769-773. (Pubitemid 40292988)
20. Zaballos A, Varona R, Gutiérrez J, Lind P, Márquez G. Molecular cloning and RNA expression of two new human chemokine receptor-like genes. Biochem Biophys Res Commun. 1996;227(3):846-853. (Pubitemid 26387814)
21. Baba M, Imai T, Nishimura M, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Biol Chem. 1997;272(23):14893-14898. (Pubitemid 27251760)
22. Ghadjar P, Rubie C, Aebersold DM, Keilholz U. The chemokine CCL20 and its receptor CCR6 in human malignancy with focus on colorectal cancer. Int J Cancer. 2009;125(4):741-745.
23. Wang L, Qin H, Li L, et al. Overexpression of CCL20 and its receptor CCR6 predicts poor clinical prognosis in human gliomas. Med Oncol. 2012;29(5):3491-3497.
24. Miyagaki T, Sugaya M, Suga H, et al. IL-22, but not IL-17, dominant environment in cutaneous T-cell lymphoma. Clin Cancer Res. 2011;17(24): 7529-7538.
25. Xiao C, Calado DP, Galler G, et al. MiR-150 controls B cell differentiation by targeting the transcription factor c-Myb. Cell. 2007;131(1):146-159. (Pubitemid 47498525)
26. Ghisi M, Corradin A, Basso K, et al. Modulation of microRNA expression in human T-cell development: targeting of NOTCH3 by miR-150. Blood. 2011;117(26):7053-7062.
27. Lewis BP, Shih IH, Jones-Rhoades MW, Bartel DP, Burge CB. Prediction of mammalian microRNA targets. Cell. 2003;115(7):787-798. (Pubitemid 38058492)
28. Duhen T, Geiger R, Jarrossay D, Lanzavecchia A, Sallusto F. Production of interleukin 22 but not interleukin 17 by a subset of human skin-homing memory T cells. Nat Immunol. 2009;10(8):857-863.
29. Harper EG, Guo C, Rizzo H, et al. Th17 cytokines stimulate CCL20 expression in keratinocytes in vitro and in vivo: implications for psoriasis pathogenesis. J Invest Dermatol. 2009;129(9): 2175-2183.
30. Trifari S, Kaplan CD, Tran EH, Crellin NK, Spits H. Identification of a human helper T cell population that has abundant production of interleukin 22 and is distinct from T(H)-17, T(H)1 and T(H)2 cells. Nat Immunol. 2009;10(8):864-871.
31. Schutyser E, Struyf S, Van Damme J. The CC chemokine CCL20 and its receptor CCR6. Cytokine Growth Factor Rev. 2003;14(5):409-426. (Pubitemid 37099454)
32. Brand S, Olszak T, Beigel F, et al. Cell differentiation dependent expressed CCR6 mediates ERK-1/2, SAPK/JNK, and Akt signaling resulting in proliferation and migration of colorectal cancer cells. J Cell Biochem. 2006; 97(4):709-723.
33. Kirshberg S, Izhar U, Amir G, et al. Involvement of CCR6/CCL20/IL-17 axis in NSCLC disease progression. PLoS ONE. 2011;6(9):e24856.
34. Fusi A, Liu Z, Kümmerlen V, Nonnemacher A, Jeske J, Keilholz U. Expression of chemokine receptors on circulating tumor cells in patients with solid tumors. J Transl Med. 2012;10(1):52.
35. Oldham KA, Parsonage G, Bhatt RI, et al. T lymphocyte recruitment into renal cell carcinoma tissue: a role for chemokine receptors CXCR3, CXCR6, CCR5, and CCR6. Eur Urol. 2012;61(2):385-394.
36. Wolk K, Sabat R. Interleukin-22: a novel T- and NK-cell derived cytokine that regulates the biology of tissue cells. Cytokine Growth Factor Rev. 2006; 17(5):367-380. (Pubitemid 44572879)
37. Bard JD, Gelebart P, Anand M, Amin HM, Lai R. Aberrant expression of IL-22 receptor 1 and autocrine IL-22 stimulation contribute to tumorigenicity in ALK1 anaplastic large cell lymphoma. Leukemia. 2008;22(8):1595-1603.
38. Gelebart P, Zak Z, Dien-Bard J, Anand M, Lai R. Interleukin 22 signaling promotes cell growth in mantle cell lymphoma. Transl Oncol. 2011;4(1):9-19.
39. Willemze R, Jaffe ES, Burg G, et al. WHOEORTC classification for cutaneous lymphomas. Blood. 2005;105(10):3768-3785.
40. Ralfkiaer E, Cerroni L, Sander CA, Smoller BR, Willemze R. Mycosis fungoides. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumours of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:296-298.
41. Ralfkiaer E, Willemze R, Whittaker SJ. Sézary syndrome. In: Swerdlow SH, Campo E, Harris NL, et al, eds. World Health Organization Classification of Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press; 2008:299-300.
42. Tagawa H, Karube K, Tsuzuki S, Ohshima K, Seto M. Synergistic action of the microRNA-17 polycistron and Myc in aggressive cancer development. Cancer Sci. 2007;98(9):1482-1490. (Pubitemid 47241774)
43. Inomata M, Tagawa H, Guo YM, Kameoka Y, Takahashi N, Sawada K. MicroRNA-17-92 downregulates expression of distinct targets in different B-cell lymphoma subtypes. Blood. 2009;113(2):396-402.
44. Yamanaka Y, Tagawa H, Takahashi N, et al. Aberrant overexpression of microRNAs activate AKT signaling via down-regulation of tumor suppressors in natural killer-cell lymphoma/ leukemia. Blood. 2009;114(15):3265-3275.
45. Liu H, Rohowsky-Kochan C. Regulation of IL-17 in human CCR6+ effector memory T cells. J Immunol. 2008;180(12):7948-7957.
46. Singh SP, Zhang HH, Foley JF, Hedrick MN, Farber JM. Human T cells that are able to produce IL-17 express the chemokine receptor CCR6. J Immunol. 2008;180(1):214-221.
47. Eyerich S, Eyerich K, Pennino D, et al. Th22 cells represent a distinct human T cell subset involved in epidermal immunity and remodeling. J Clin Invest. 2009;119(12):3573-3585.